149 related articles for article (PubMed ID: 32380355)
1. Determination of clobetasol propionate, tazarotene and tazarotenic acid in Bama mini-pig skin by UPLC-MS/MS: Application to pharmacokinetic and drug-drug interaction studies.
Lu YT; Guan R; Zheng JR; Hang TJ; Song M
J Pharm Biomed Anal; 2020 Jul; 186():113322. PubMed ID: 32380355
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous determination of tazarotene, clindamycin phosphate and their active metabolites in Bama mini-pig skin by LC-MS/MS: Application to the development of a tazarotene/clindamycin phosphate cream.
Lu YT; Hu ZL; Shao FX; Song M; Hang TJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jan; 1162():122455. PubMed ID: 33360677
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous determination of tazarotene and its active metabolite tazarotenic acid in minipig plasma by LC-MS/MS and its application in pharmacokinetic study after topical administration of tazarotene gel.
Tong Y; Pan H; Sun C; Xin X; Ding L; Ma P
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Jan; 978-979():173-8. PubMed ID: 25550192
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis.
Tang-Liu DD; Matsumoto RM; Usansky JI
Clin Pharmacokinet; 1999 Oct; 37(4):273-87. PubMed ID: 10554045
[TBL] [Abstract][Full Text] [Related]
5. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study.
Bowman PH; Maloney JE; Koo JY
J Am Acad Dermatol; 2002 Jun; 46(6):907-13. PubMed ID: 12063489
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of tazarotene cream 0.1% after a single dose and after repeat topical applications at clinical or exaggerated application rates in patients with acne vulgaris or photodamaged skin.
Yu Z; Sefton J; Lew-Kaya D; Walker P; Yu D; Tang-Liu DD
Clin Pharmacokinet; 2003; 42(10):921-9. PubMed ID: 12885265
[TBL] [Abstract][Full Text] [Related]
7. Comparison of clinical efficacy of topical tazarotene 0.1% cream with topical clobetasol propionate 0.05% cream in chronic plaque psoriasis: a double-blind, randomized, right-left comparison study.
Angelo JS; Kar BR; Thomas J
Indian J Dermatol Venereol Leprol; 2007; 73(1):65. PubMed ID: 17319037
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of change in the skin concentration of tazarotene and betamethasone dipropionate based on drug-drug interaction for transdermal drug delivery in miniature pig.
Yu B; Ma P; Yuan L; Chen D; Yang J
Xenobiotica; 2015 May; 45(5):380-4. PubMed ID: 25410121
[TBL] [Abstract][Full Text] [Related]
9. The role of tazarotene in the treatment of psoriasis.
Marks R
Br J Dermatol; 1999 Apr; 140 Suppl 54():24-8. PubMed ID: 10731131
[TBL] [Abstract][Full Text] [Related]
10. A novel halobetasol propionate 0.01%/tazarotene 0.045% fixed combination treatment for psoriasis.
Radonjic A; Evans EL
Dermatol Ther; 2019 Jul; 32(4):e12979. PubMed ID: 31155813
[No Abstract] [Full Text] [Related]
11. Formulation development of tazarotene-loaded PLGA nanoparticles for follicular delivery in the treatment of inflammatory skin diseases.
Kshirsagar SM; Shrestha N; Kipping T; Banga AK
Eur J Pharm Biopharm; 2024 Jul; 200():114346. PubMed ID: 38823541
[TBL] [Abstract][Full Text] [Related]
12. Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study.
Rigopoulos D; Gregoriou S; Katsambas A
Acta Derm Venereol; 2007; 87(2):167-8. PubMed ID: 17340027
[No Abstract] [Full Text] [Related]
13. Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials.
Ramachandran V; Bertus B; Bashyam AM; Feldman SR
Ann Pharmacother; 2020 Sep; 54(9):872-878. PubMed ID: 32126800
[No Abstract] [Full Text] [Related]
14. Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis.
Lebwohl MG; Sugarman JL; Gold LS; Pariser DM; Lin T; Pillai R; Martin G; Harris S; Israel R
J Am Acad Dermatol; 2019 Jan; 80(1):282-285. PubMed ID: 30227193
[No Abstract] [Full Text] [Related]
15. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
[TBL] [Abstract][Full Text] [Related]
16. Tazarotene foam versus tazarotene gel: a randomized relative bioavailability study in acne vulgaris.
Jarratt M; Werner CP; Alió Saenz AB
Clin Drug Investig; 2013 Apr; 33(4):283-9. PubMed ID: 23456673
[TBL] [Abstract][Full Text] [Related]
17. Development of a simple method for simultaneous determination of tazarotene and betamethasone dipropionate and their metabolites using LC-MS method and its application to dermatopharmacokinetic study.
Li L; Zhang M; Ma P; Qian K
Biomed Chromatogr; 2019 Aug; 33(8):e4557. PubMed ID: 30990899
[TBL] [Abstract][Full Text] [Related]
18. Disposition and biotransformation of the acetylenic retinoid tazarotene in humans.
Attar M; Yu D; Ni J; Yu Z; Ling KH; Tang-Liu DD
J Pharm Sci; 2005 Oct; 94(10):2246-55. PubMed ID: 16136553
[TBL] [Abstract][Full Text] [Related]
19. Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive.
Yu Z; Yu D; Walker PS; Tang-Liu DD
Clin Pharmacokinet; 2004; 43(10):673-84. PubMed ID: 15244497
[TBL] [Abstract][Full Text] [Related]
20. Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments.
Lebwohl M; Lombardi K; Tan MH
Int J Dermatol; 2001 Jan; 40(1):64-6. PubMed ID: 11277960
[No Abstract] [Full Text] [Related]
[Next] [New Search]
